MET Exon 14 Skipping Mutations: Essential Considerations for Current Management of Non –Small Cell Lung Cancer

Genetic alterations in MET that lead to exclusion of exon 14 from the transcript are now targetable in non –small cell lung cancer (NSCLC) after recent drug approvals for this indication. However, this class of alteration is much more diverse than activating mutations in other targetable oncogenes, which presents challenges for clinical detection by molecular diagnostic assays. For this reason, MET exo n 14 (METex14) skipping was highlighted in the Association for Molecular Pathology Emerging and Evolving Biomarkers webinar series (https://www.amp.org/education/emerging-and-evolving-biomarkers, last accessed April 26, 2022).
Source: Journal of Molecular Diagnostics - Category: Pathology Authors: Tags: Practice advances Source Type: research